GlucoTrack Inc. Common Stock (GCTK)

FairStock Score: 65/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at GlucoTrack through a Graham-and-Buffett lens, I start with business quality and find very little to underwrite. It is a 15-employee medical device company with no reported revenue in the filed periods, trying to develop an implantable continuous blood glucose monitor. That is a promising idea, but an idea is not a moat. There is no pricing power, no recurring revenue, no installed base, and no evidence of durable competitive advantage. Financial health is poor. The company lost $19.4 million in fiscal year 2025, $22.6 million in fiscal year 2024, and $7.1 million in fiscal year 2023; in fiscal Q2 2026, the quarter ended 2026-06-30, it lost $3.8 million, and in fiscal Q1 2026 it lost $4.3 million. Trailing free cash flow was negative $16.3 million, against a $1.4 million market cap at the $1.11 close on 2026-10-13. FairStock's ratios reinforce the danger: ROE -620.63%, ROCE -164.45%, D/E 1.22, Piotroski 0/9, Altman Z -150.85, and FCF yield -1164.8%. Yes, P/B is 0.21 and P/E is 0.06, but with net losses and huge cash burn, those headline multiples are not meaningful margin-of-safety signals. Growth is not revenue growth; it is only a narrowing loss from FY2024 to FY2025, and FairStock's 19.81% profit growth is measured from negative earnings. The Lynch screen rightly finds no category because the company has lost money in each of the last four years. This is a speculative clinical-stage bet, not a Graham bargain. Until revenue and self-funding cash flow appear, the investment case rests almost entirely on financing and future regulatory success.

In plain English: GlucoTrack is a very small medical device company trying to develop an implantable blood sugar monitor for people with diabetes. It has no reported revenue and has lost money in each of the last four years, so the business looks weak and unproven. At $1.11 a share and a $1.4 million total market value, some calculated numbers make it look very cheap, but those numbers are distorted by losses and heavy spending, so it looks speculative rather than a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer